Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 73 to 77 of 77 entries
Sorted by: Best Match Show Resources per page
'It is good to have a target in mind': qualitative views of patients and parents informing a treat to target clinical trial in juvenile-onset systemic lupus erythematosus.

Rheumatology (Oxford, England)

Smith EMD, Gorst SL, Al-Abadi E, Hawley DP, Leone V, Pilkington C, Ramanan AV, Rangaraj S, Sridhar A, Beresford MW, Young B.
PMID: 33629109
Rheumatology (Oxford). 2021 Dec 01;60(12):5630-5641. doi: 10.1093/rheumatology/keab173.

OBJECTIVE: We sought to explore patient and parental views on treatment targets, outcome measures and study designs being considered for a future JSLE treat-to-target (T2T) study.METHODS: We conducted topic-guided, semistructured interviews with JSLE patients and parents and analysed the...

Cite
Smith EMD, Gorst SL, Al-Abadi E, et al. 'It is good to have a target in mind': qualitative views of patients and parents informing a treat to target clinical trial in juvenile-onset systemic lupus erythematosus. Rheumatology (Oxford). 2021;60(12):5630-5641doi: 10.1093/rheumatology/keab173.
Smith, E. M. D., Gorst, S. L., Al-Abadi, E., Hawley, D. P., Leone, V., Pilkington, C., Ramanan, A. V., Rangaraj, S., Sridhar, A., Beresford, M. W., & Young, B. (2021). 'It is good to have a target in mind': qualitative views of patients and parents informing a treat to target clinical trial in juvenile-onset systemic lupus erythematosus. Rheumatology (Oxford, England), 60(12), 5630-5641. https://doi.org/10.1093/rheumatology/keab173
Smith, Eve M D, et al. "'It is good to have a target in mind': qualitative views of patients and parents informing a treat to target clinical trial in juvenile-onset systemic lupus erythematosus." Rheumatology (Oxford, England) vol. 60,12 (2021): 5630-5641. doi: https://doi.org/10.1093/rheumatology/keab173
Smith EMD, Gorst SL, Al-Abadi E, Hawley DP, Leone V, Pilkington C, Ramanan AV, Rangaraj S, Sridhar A, Beresford MW, Young B. 'It is good to have a target in mind': qualitative views of patients and parents informing a treat to target clinical trial in juvenile-onset systemic lupus erythematosus. Rheumatology (Oxford). 2021 Dec 01;60(12):5630-5641. doi: 10.1093/rheumatology/keab173. PMID: 33629109; PMCID: PMC8645274.
Copy Download .nbib Format: NLM
Real-World Experience in Toxicity with Bevacizumab in Indian Cancer Patients.

South Asian journal of cancer

Patil PP, Rangaraju RR, Abbas W, Garg S.
PMID: 34568227
South Asian J Cancer. 2021 Apr;10(2):131-134. doi: 10.1055/s-0041-1729445. Epub 2021 Sep 04.

No abstract available.

Cite
Patil PP, Rangaraju RR, Abbas W, et al. Real-World Experience in Toxicity with Bevacizumab in Indian Cancer Patients. South Asian J Cancer. 2021;10(2):131-134doi: 10.1055/s-0041-1729445.
Patil, P. P., Rangaraju, R. R., Abbas, W., & Garg, S. (2021). Real-World Experience in Toxicity with Bevacizumab in Indian Cancer Patients. South Asian journal of cancer, 10(2), 131-134. https://doi.org/10.1055/s-0041-1729445
Patil, Pratik P, et al. "Real-World Experience in Toxicity with Bevacizumab in Indian Cancer Patients." South Asian journal of cancer vol. 10,2 (2021): 131-134. doi: https://doi.org/10.1055/s-0041-1729445
Patil PP, Rangaraju RR, Abbas W, Garg S. Real-World Experience in Toxicity with Bevacizumab in Indian Cancer Patients. South Asian J Cancer. 2021 Apr;10(2):131-134. doi: 10.1055/s-0041-1729445. Epub 2021 Sep 04. PMID: 34568227; PMCID: PMC8460349.
Copy Download .nbib Format: NLM
Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis.

Arthritis & rheumatology (Hoboken, N.J.)

Brogan P, Yeung RSM, Cleary G, Rangaraj S, Kasapcopur O, Hersh AO, Li S, Paripovic D, Schikler K, Zeft A, Bracaglia C, Eleftheriou D, Pordeli P, Melega S, Jamois C, Gaudreault J, Michalska M, Brunetta P, Cooper JC, Lehane PB.
PMID: 34164952
Arthritis Rheumatol. 2021 Jun 23; doi: 10.1002/art.41901. Epub 2021 Jun 23.

OBJECTIVE: To assess the safety, tolerability, pharmacokinetics, and efficacy of rituximab (RTX) in pediatric patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).METHODS: The Pediatric Polyangiitis Rituximab Study was a phase IIa, international, open-label, single-arm study. During the...

Cite
Brogan P, Yeung RSM, Cleary G, et al. Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis. Arthritis Rheumatol. 2021;doi: 10.1002/art.41901.
Brogan, P., Yeung, R. S. M., Cleary, G., Rangaraj, S., Kasapcopur, O., Hersh, A. O., Li, S., Paripovic, D., Schikler, K., Zeft, A., Bracaglia, C., Eleftheriou, D., Pordeli, P., Melega, S., Jamois, C., Gaudreault, J., Michalska, M., Brunetta, P., Cooper, J. C., Lehane, P. B. (2021). Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis. Arthritis & rheumatology (Hoboken, N.J.), . https://doi.org/10.1002/art.41901
Brogan, Paul, et al. "Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis." Arthritis & rheumatology (Hoboken, N.J.) vol. (2021). doi: https://doi.org/10.1002/art.41901
Brogan P, Yeung RSM, Cleary G, Rangaraj S, Kasapcopur O, Hersh AO, Li S, Paripovic D, Schikler K, Zeft A, Bracaglia C, Eleftheriou D, Pordeli P, Melega S, Jamois C, Gaudreault J, Michalska M, Brunetta P, Cooper JC, Lehane PB. Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis. Arthritis Rheumatol. 2021 Jun 23; doi: 10.1002/art.41901. Epub 2021 Jun 23. PMID: 34164952.
Copy Download .nbib Format: NLM
Implementation research to accelerate scale-up of national screen and treat strategies towards the elimination of cervical cancer.

Preventive medicine

Broutet N, Jeronimo J, Kumar S, Almonte M, Murillo R, Huy NVQ, Denny L, Kapambwe S, Bhatla N, Sebitloane M, Zhao F, Gravitt P, Adsul P, Rangaraj A, Dalal S, Newman M, Chowdhury R, Church K, Nakisige C, Diop M, Parham G, Thomson KA, Basu P, Steyn P.
PMID: 34896155
Prev Med. 2021 Dec 08;155:106906. doi: 10.1016/j.ypmed.2021.106906. Epub 2021 Dec 08.

BACKGROUND: Cervical cancer is a significant public health problem, with 570,000 new cases and 300,000 deaths of women per year globally, mostly in low- and middle-income countries. In 2018 the WHO Director General made a call to action for...

Cite
Broutet N, Jeronimo J, Kumar S, et al. Implementation research to accelerate scale-up of national screen and treat strategies towards the elimination of cervical cancer. Prev Med. 2021;155:106906doi: 10.1016/j.ypmed.2021.106906.
Broutet, N., Jeronimo, J., Kumar, S., Almonte, M., Murillo, R., Huy, N. V. Q., Denny, L., Kapambwe, S., Bhatla, N., Sebitloane, M., Zhao, F., Gravitt, P., Adsul, P., Rangaraj, A., Dalal, S., Newman, M., Chowdhury, R., Church, K., Nakisige, C., Diop, M., Parham, G., Thomson, K. A., Basu, P., & Steyn, P. (2021). Implementation research to accelerate scale-up of national screen and treat strategies towards the elimination of cervical cancer. Preventive medicine, 155106906. https://doi.org/10.1016/j.ypmed.2021.106906
Broutet, Nathalie, et al. "Implementation research to accelerate scale-up of national screen and treat strategies towards the elimination of cervical cancer." Preventive medicine vol. 155 (2021): 106906. doi: https://doi.org/10.1016/j.ypmed.2021.106906
Broutet N, Jeronimo J, Kumar S, Almonte M, Murillo R, Huy NVQ, Denny L, Kapambwe S, Bhatla N, Sebitloane M, Zhao F, Gravitt P, Adsul P, Rangaraj A, Dalal S, Newman M, Chowdhury R, Church K, Nakisige C, Diop M, Parham G, Thomson KA, Basu P, Steyn P. Implementation research to accelerate scale-up of national screen and treat strategies towards the elimination of cervical cancer. Prev Med. 2021 Dec 08;155:106906. doi: 10.1016/j.ypmed.2021.106906. Epub 2021 Dec 08. PMID: 34896155.
Copy Download .nbib Format: NLM
Y chromosomal noncoding RNAs regulate autosomal gene expression via piRNAs in mouse testis.

BMC biology

Reddy HM, Bhattacharya R, Tiwari S, Mishra K, Annapurna P, Jehan Z, Praveena NM, Alex JL, Dhople VM, Singh L, Sivaramakrishnan M, Chaturvedi A, Rangaraj N, Shiju TM, Sreedevi B, Kumar S, Dereddi RR, Rayabandla SM, Jesudasan RA.
PMID: 34503492
BMC Biol. 2021 Sep 09;19(1):198. doi: 10.1186/s12915-021-01125-x.

BACKGROUND: Deciphering the functions of Y chromosome in mammals has been slow owing to the presence of repeats. Some of these repeats transcribe coding RNAs, the roles of which have been studied. Functions of the noncoding transcripts from Y...

Cite
Reddy HM, Bhattacharya R, Tiwari S, et al. Y chromosomal noncoding RNAs regulate autosomal gene expression via piRNAs in mouse testis. BMC Biol. 2021;19(1):198doi: 10.1186/s12915-021-01125-x.
Reddy, H. M., Bhattacharya, R., Tiwari, S., Mishra, K., Annapurna, P., Jehan, Z., Praveena, N. M., Alex, J. L., Dhople, V. M., Singh, L., Sivaramakrishnan, M., Chaturvedi, A., Rangaraj, N., Shiju, T. M., Sreedevi, B., Kumar, S., Dereddi, R. R., Rayabandla, S. M., & Jesudasan, R. A. (2021). Y chromosomal noncoding RNAs regulate autosomal gene expression via piRNAs in mouse testis. BMC biology, 19(1), 198. https://doi.org/10.1186/s12915-021-01125-x
Reddy, Hemakumar M, et al. "Y chromosomal noncoding RNAs regulate autosomal gene expression via piRNAs in mouse testis." BMC biology vol. 19,1 (2021): 198. doi: https://doi.org/10.1186/s12915-021-01125-x
Reddy HM, Bhattacharya R, Tiwari S, Mishra K, Annapurna P, Jehan Z, Praveena NM, Alex JL, Dhople VM, Singh L, Sivaramakrishnan M, Chaturvedi A, Rangaraj N, Shiju TM, Sreedevi B, Kumar S, Dereddi RR, Rayabandla SM, Jesudasan RA. Y chromosomal noncoding RNAs regulate autosomal gene expression via piRNAs in mouse testis. BMC Biol. 2021 Sep 09;19(1):198. doi: 10.1186/s12915-021-01125-x. PMID: 34503492; PMCID: PMC8428117.
Copy Download .nbib Format: NLM
Showing 73 to 77 of 77 entries